多配体蛋白聚糖2在非小细胞肺癌中异常表达的临床意义
|
摘要
目的研究多配体蛋白聚糖2(SDC2)在非小细胞肺癌(NSCLC)组织中表达的临床病理意义。方法收集2015年1月～2017年1月河北省秦皇岛市第一医院73例手术切除NSCLC组织为NSCLC组,采用免疫组织化学染色法检测SDC2在癌组织中的表达,并以相应癌旁正常组织作为对照组。分析SDC2在NSCLC组织中的差异表达。结果与对照组比较,SDC2在NSCLC组中的阳性表达显著升高,其异常高表达与肺癌分化程度和TMN分期关系密切(P <0.05)。结论 SDC2在NSCLC的异常表达可能是肺癌诊断治疗的靶点之一。
Objective To study the clinical significance of SDC2 in non small cell lung cancer(NSCLC). Methods The surgical resections of NSCLC tissues of 73 cases were collected in the First Hospital of Qinhuangdao City in Hebei Province from January 2015 to January 2017 as NSCLC group. The expression of SDC2 was masured by IHC staining of NSCLC compared with normal tissue adjacent to cancer(control group). Results Compared with control group, the positive expression of SDC2 was increased in NSCLC and had a realtionship with cancer differentation and TNM stages(P <0.05). Conclusion SDC2 may be one of potentail targets for dignosis and treatment of NSCLC.
Objective To study the clinical significance of SDC2 in non small cell lung cancer(NSCLC). Methods The surgical resections of NSCLC tissues of 73 cases were collected in the First Hospital of Qinhuangdao City in Hebei Province from January 2015 to January 2017 as NSCLC group. The expression of SDC2 was masured by IHC staining of NSCLC compared with normal tissue adjacent to cancer(control group). Results Compared with control group, the positive expression of SDC2 was increased in NSCLC and had a realtionship with cancer differentation and TNM stages(P <0.05). Conclusion SDC2 may be one of potentail targets for dignosis and treatment of NSCLC.
引文
[1]Rosell R,Karachaliou N. Large-scale screening for somatic mutations in lung cancer[J]. Lancet,2016,387(10026):1354-1356.
[2]Cho BC,DE Pas T,Kalofonos H,et al. Prognostic factors in early-stage NSCLC:analysis of the placebo group in the MAGRIT study[J]. Anticancer Res,2019,39(3):1403-1409.
[3]Pataki CA,Couchman JR,Brábek J. Wnt signaling cascades and the roles of syndecan proteoglycans[J]. J Histochem Cytochem,2015,63(7):465-480.
[4]Kramer KL,Yost HJ. Heparan sulfate core proteins in cellcell signaling[J]. Annu Rev Gene,2003,37:461-484.
[5]Mytilinaiou M,Nikitovic D,Berdiaki A,et al. Emerging roles of syndecan 2 in epithelial and mesenchymal cancer progression[J]. IUBMB Life,2017,69(11):824-833.
[6]Vicente CM,Ricci R,Nader HB,et al. Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts[J].BMC Cell Biol,2013,14:25.
[7]Jang B,Jung H,Chung H,et al. Syndecan-2 enhances Ecadherin shedding and fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells[J]. Biochem Biophys Res Commun,2016,477(1):47-53.
[8]Popovic'A,Demirovic'A,Spajic'B,et al. Expression and prognostic role of syndecan-2 in prostate cancer[J].Prostate Cancer Prostatic Dis,2010,13(1):78-82.
[9]Sun M,Gomes S,Chen P,et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2[J]. Oncogene,2014,33(27):3528-3537.
[10]Huang X,Xiao DW,Xu LY,et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma[J]. Oncol Rep,2009,21(4):1123-1129.
[11]Wan Y,Belt A,Wang Z,et al. Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes[J]. Int J Mol Med,2001,7(3):329-334.
[12]Mytilinaiou M,Nikitovic D,Berdiaki A,et al. IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis[J]. Exp Cell Res,2017,361(1):9-18.
[13]Huang JW,Chen CL,Chuang NN. P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras[J]. Biochem Biophys Res Commun,2005,329(3):855-862.
[14]Lee YH,Park JH,Cheon DH,et al. Processing of syndecan-2 by matrix metalloproteinase-14 and effect of its cleavage on VEGF-induced tube formation of HUVECs[J].Biochem J,2017,474(22):3719-3732.
[15]Liu Y,Ni R,Zhang H,et al. Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data[J]. Onco Targets Ther,2016,9:7397-7407.
[16]Li TT,Gao X,Gao L,et al. Role of upregulated miR-136-5p in lung adenocarcinoma:a study of 1242 samples utilizing bioinformatics analysis[J]. Pathol Res Pract,2018,214(5):750-766.
[17]Jang B,Jung H,Choi S,et al. Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer[J]. J Biol Chem,2017,292(39):16321-16332.
[18]Mytilinaiou M,Bano A,Nikitovic D,et al. Syndecan-2 is a key regulator of transforming growth factor beta 2/smad2-mediated adhesion in fibrosarcoma cells[J]. IUBMB Life,2013,65(2):134-143.
[19]Yang X,Deng Y,He RQ,et al. Upregulation of HOXA11during the progression of lung adenocarcinoma detected via multiple approaches[J]. Int J Mol Med,2018,42(5):2650-2664.
[20]Zhao F,Pu Y,Cui M,et al. MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene[J]. Cancer Cell Int,2017,17:100.
[21]Cai X,Yang X,Jin C,et al. Identification and verification of differentially expressed microRNAs and their target genes for the diagnosis of esophageal cancer[J]. Oncol Lett,2018,16(3):3642-3650.
[22]Park YS,Kim DS,Cho SW,et al. Analysis of syndecan-2methylation in bowel lavage fluid for the detection of colorectal neoplasm[J]. Gut Liver,2018,12(5):508-515.
[23]Niu F,Wen J,Fu X,et al. Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia[J]. Cancer Epidemiol Biomarkers Prev,2017,26(9):1411-1419.
[2]Cho BC,DE Pas T,Kalofonos H,et al. Prognostic factors in early-stage NSCLC:analysis of the placebo group in the MAGRIT study[J]. Anticancer Res,2019,39(3):1403-1409.
[3]Pataki CA,Couchman JR,Brábek J. Wnt signaling cascades and the roles of syndecan proteoglycans[J]. J Histochem Cytochem,2015,63(7):465-480.
[4]Kramer KL,Yost HJ. Heparan sulfate core proteins in cellcell signaling[J]. Annu Rev Gene,2003,37:461-484.
[5]Mytilinaiou M,Nikitovic D,Berdiaki A,et al. Emerging roles of syndecan 2 in epithelial and mesenchymal cancer progression[J]. IUBMB Life,2017,69(11):824-833.
[6]Vicente CM,Ricci R,Nader HB,et al. Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts[J].BMC Cell Biol,2013,14:25.
[7]Jang B,Jung H,Chung H,et al. Syndecan-2 enhances Ecadherin shedding and fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells[J]. Biochem Biophys Res Commun,2016,477(1):47-53.
[8]Popovic'A,Demirovic'A,Spajic'B,et al. Expression and prognostic role of syndecan-2 in prostate cancer[J].Prostate Cancer Prostatic Dis,2010,13(1):78-82.
[9]Sun M,Gomes S,Chen P,et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2[J]. Oncogene,2014,33(27):3528-3537.
[10]Huang X,Xiao DW,Xu LY,et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma[J]. Oncol Rep,2009,21(4):1123-1129.
[11]Wan Y,Belt A,Wang Z,et al. Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes[J]. Int J Mol Med,2001,7(3):329-334.
[12]Mytilinaiou M,Nikitovic D,Berdiaki A,et al. IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis[J]. Exp Cell Res,2017,361(1):9-18.
[13]Huang JW,Chen CL,Chuang NN. P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras[J]. Biochem Biophys Res Commun,2005,329(3):855-862.
[14]Lee YH,Park JH,Cheon DH,et al. Processing of syndecan-2 by matrix metalloproteinase-14 and effect of its cleavage on VEGF-induced tube formation of HUVECs[J].Biochem J,2017,474(22):3719-3732.
[15]Liu Y,Ni R,Zhang H,et al. Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data[J]. Onco Targets Ther,2016,9:7397-7407.
[16]Li TT,Gao X,Gao L,et al. Role of upregulated miR-136-5p in lung adenocarcinoma:a study of 1242 samples utilizing bioinformatics analysis[J]. Pathol Res Pract,2018,214(5):750-766.
[17]Jang B,Jung H,Choi S,et al. Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer[J]. J Biol Chem,2017,292(39):16321-16332.
[18]Mytilinaiou M,Bano A,Nikitovic D,et al. Syndecan-2 is a key regulator of transforming growth factor beta 2/smad2-mediated adhesion in fibrosarcoma cells[J]. IUBMB Life,2013,65(2):134-143.
[19]Yang X,Deng Y,He RQ,et al. Upregulation of HOXA11during the progression of lung adenocarcinoma detected via multiple approaches[J]. Int J Mol Med,2018,42(5):2650-2664.
[20]Zhao F,Pu Y,Cui M,et al. MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene[J]. Cancer Cell Int,2017,17:100.
[21]Cai X,Yang X,Jin C,et al. Identification and verification of differentially expressed microRNAs and their target genes for the diagnosis of esophageal cancer[J]. Oncol Lett,2018,16(3):3642-3650.
[22]Park YS,Kim DS,Cho SW,et al. Analysis of syndecan-2methylation in bowel lavage fluid for the detection of colorectal neoplasm[J]. Gut Liver,2018,12(5):508-515.
[23]Niu F,Wen J,Fu X,et al. Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia[J]. Cancer Epidemiol Biomarkers Prev,2017,26(9):1411-1419.